Propanc Biopharma raises $100 million for crypto reserves and cancer therapy research.

Propanc Biopharma, a US-listed biopharmaceutical company, has raised up to $100 million in funding from Hexstone Capital's family office. The funds will be used to establish a digital asset portfolio and expedite the development of its flagship cancer therapy, PRP. The company received an initial investment of $1 million and has the potential to receive an additional $99 million within the next year. Propanc's stock price declined despite the financing news.